The medication vibegron led to improvements in symptoms of overactive bladder and overall quality of life in men undergoing treatment for benign prostatic hyperplasia, according to findings from a ...

Chinese investigators evaluated 15 years' worth of data from more than 18,000 adult men in the U.S. to better characterize OAB and its risk factors. The overall presence of OAB increased significantly ...

A study of NHANES 2005-2020 data found that the prevalence of overactive bladder among men in the US increased significantly from 11.7% in 2009-2014 to 14.5% in 2015-2020. Overactive bladder (OAB) ...

Men with overactive bladder had significant 95% reduced odds of urinary tract cancers compared with a reference group of men with urolithiasis, after adjusting for age. Overactive bladder (OAB) is ...

Please provide your email address to receive an email when new articles are posted on . The proportion of men with overactive bladder increased significantly from 2015 to 2020. Results showed ...

"My bladder is ruining my life," Mr. X said as he sat down on the exam table, already nervous about his first time seeing a urologist. He had considered skipping his appointment, but he simply can't ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign prostatic ...

In the United States today, overactive bladder (OAB) may impact as many as 40 percent of women and 30 percent of men. The chances of developing OAB increase with age but the condition is not a ...

Aggression was more prevalent in men with OAB or LUTS than in men without either condition and contributed to poorer quality of life. The difference in quality of life was statistically significant ...

Structured behavioral therapy focused on pelvic floor muscle exercise was noninferior to treatment with solifenacin for alleviating overactive bladder symptoms in patients with Parkinson’s disease (PD ...